Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89,134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, Wisemandle W, Soares H, Baniecki ML, Hendrick VM, Kalfov V, Pypstra R, Rusnak JM. Hammond J, et al. Among authors: zhang w. N Engl J Med. 2024 Jul 18;391(3):224-234. doi: 10.1056/NEJMoa2309002. N Engl J Med. 2024. PMID: 39018532 Free PMC article. Clinical Trial.
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, Vranic I, Zhang W, Alten R. Fleischmann RM, et al. Among authors: zhang w. Arthritis Res Ther. 2021 Sep 25;23(1):248. doi: 10.1186/s13075-021-02626-4. Arthritis Res Ther. 2021. PMID: 34563243 Free PMC article. Clinical Trial.
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.
Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, Vranic I, Zhang W, Alten R. Fleischmann RM, et al. Among authors: zhang w. RMD Open. 2021 Apr;7(2):e001578. doi: 10.1136/rmdopen-2021-001578. RMD Open. 2021. PMID: 33883254 Free PMC article. Clinical Trial.
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.
Fleischmann RM, Saikali W, Lakhanpal S, Alvarez DF, Cox DS, Ianos CA, Zhang W, Cronenberger C, Wang K. Fleischmann RM, et al. Among authors: zhang w. Lancet Rheumatol. 2023 Sep;5(9):e532-e541. doi: 10.1016/S2665-9913(23)00161-3. Epub 2023 Aug 21. Lancet Rheumatol. 2023. PMID: 38251497 Clinical Trial.
Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial.
Liu C, Guo C, Li F, Yu N, Huang J, Peng Z, Kong W, Song J, Liu X, Fan S, Yue C, Chen B, Zheng C, Yuan X, Sheng J, Wu Y, Sun B, Zhao Z, Zhu M, Han L, Shi Q, Xia Z, Shang X, Li F, Li R, Yue F, Jiang S, Song D, Song M, Shan Y, Ding C, Yao L, Yang Y, Chen J, He W, Pan F, Zhang W, Cai T, Han S, Li W, Li G, Gong C, Huang L, Huang C, Wang D, Kaesmacher J, Nguyen TN, Nogueira RG, Saver JL, Zi W, Chen Y, Yang Q; POST-UK investigators. Liu C, et al. Among authors: zhang w. JAMA. 2025 Jan 13. doi: 10.1001/jama.2024.23480. Online ahead of print. JAMA. 2025. PMID: 39804674
89,134 results
You have reached the last available page of results. Please see the User Guide for more information.